In a recent safety communication, the U.S. Food and Drug Administration (FDA) issued a warning to consumers, patients, and health care providers about serious complications reported in connection with certain
As dermatology continues to embrace diversity and inclusivity, increasing attention is being paid to the unique needs of patients with skin of color. A recent reanalysis of a study in
The FDA has approved adalimumab-aaty (YUFLYMA; Celltrion, Inc.) for the treatment of adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV) in the U.S. This approval, which covers both YUFLYMA and
The FDA has approved cemiplimab-rwlc (Libtayo; Regeneron Pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk for recurrence following surgery and radiation. This
The FDA has approved roflumilast (Zoryve, Arcutis), a once-daily, steroid-free cream for the topical treatment of mild-to-moderate atopic dermatitis (AD) in children aged 2 to 5 years. This approval marks
The FDA recently approved remibrutinib (Rhapsido, Novartis), the first and only oral, targeted Bruton’s tyrosine kinase inhibitor (BTKi) for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite
Atopic dermatitis (AD) remains the most common chronic inflammatory skin condition, with persistent itch, barrier dysfunction, and inflammation continuing to drive significant disease burden. These ongoing challenges highlight the critical
A new, large-scale study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 has revealed a significant association between atopic eczema (AE) and suicidal ideation in adults.
Two recent clinical trial updates highlight the growing momentum of OX40-targeted therapies for atopic dermatitis (AD), underscoring an emerging strategy for long-term disease control. Sanofi’s Amlitelimab Sanofi recently announced positive
Arcutis Biotherapeutics recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment
Alopecia areata is an autoimmune disease that triggers sudden and often unpredictable hair loss that continues to pose significant challenges for both patients and clinicians. While recent FDA approvals of
Melasma remains one of the most challenging pigmentary conditions for dermatologists to manage. Despite the availability of multiple treatment modalities, limitations in diagnostic tools have often made it difficult to
As the popularity of GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) continues to grow, so too does the conversation around their aesthetic side effects. The term “Ozempic face” has made
The FDA’s recent Fast Track designation of rezpegaldesleukin represents more than just progress for patients with alopecia areata; it’s a bellwether for the broader evolution of autoimmune dermatologic care. As
In a landmark decision that’s poised to transform chronic hand eczema (CHE) management, the U.S. Food and Drug Administration (FDA) has approved delgocitinib cream 2%, making it the first and
A growing body of research is reshaping how clinicians approach systemic lupus erythematosus (SLE), placing the dermatology industry at the center of this shift. A recent study led by researchers
At a recent Cleveland Clinic AI Summit, health care leaders painted a picture of artificial intelligence (AI) not as a replacement for clinicians, but as an enhancement, comparing it to
Artificial intelligence (AI) continues to make waves in medicine, offering powerful capabilities in image analysis, pattern recognition, and decision support. In dermatology and beyond, AI systems are increasingly promoted as
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition influenced by genetic, immunologic, and environmental factors. While dermatologists have long considered irritants and allergens in disease management, a growing
Emerging research is reframing how dermatologists should perceive psoriasis – not only as a dermatologic condition but also as one closely tied to metabolic health. Recent data from the UK
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
